Presentations
Presentations
Our Key Presentations
RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (Abstract)
RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (Abstract)
First-in-human study of RAG-01, a novel small activating RNA therapeutic in BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC) patients(Abstract)
First-in-human study of RAG-01, a novel small activating RNA therapeutic in BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC) patients(Abstract)
Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment. (Abstract)
Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment. (Abstract)
RAG-17: A Promising Novel Gene Silencing Therapy for SOD1-ALS Preliminary Safety and Efficacy Data from a First-in-Human Trial (Abstract)
RAG-17: A Promising Novel Gene Silencing Therapy for SOD1-ALS Preliminary Safety and Efficacy Data from a First-in-Human Trial (Abstract)
Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)
Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)
Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)
